Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

2,000 people have been recruited into the world’s largest clinical trial to test the clinical and cost effectiveness of the controversial flu drug oseltamivir (Tamiflu) in primary care. The trial aims to clear up the widespread uncertainty over whether people with flu symptoms should be treated with antiviral drugs in the community.

Led in the UK by researchers in Oxford University’s Nuffield Department of Primary Care Health Sciences, the ALIC4E trial investigates whether oseltamivir is cost effective and beneficial to patients consulting their General Practitioner with flu symptoms. In particular, it will understand if older people, infants, people with other health conditions, those treated early, or those with particularly severe flu can benefit from the treatment.

Find out more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.